Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer
CA 2395832 A1 · Owner: Genentech, Inc. · Inventors: Goddard, Audrey; Hongo, Jo-Anne S.; De Sauvage, Frederic
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention concerns compositions and methods for the treatment of disorders characterized by the overexpression of an LIV-1. More specifically the compositions include DNA and amino acid sequences of an LIV-1 antibodies , to an LIV-1, and methods for the treatment of a mammal susceptible to or diagnosed with cancer wherein an LIV-1 is overexpressed.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 25, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 25, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 25, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.